332 related articles for article (PubMed ID: 32781451)
1. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
3. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
4. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
5. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
6. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
7. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
8. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
9. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
10. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
11. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
13. Review of venom immunotherapy at a regional tertiary paediatric centre.
Johnston N; Belcher J; Preece K; Bhatia R
J Paediatr Child Health; 2022 Jul; 58(7):1228-1232. PubMed ID: 35416342
[TBL] [Abstract][Full Text] [Related]
14. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
15. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.
Birnbaum J; Ramadour M; Magnan A; Vervloet D
Clin Exp Allergy; 2003 Jan; 33(1):58-64. PubMed ID: 12534550
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.
Stoevesandt J; Hain J; Stolze I; Kerstan A; Trautmann A
Clin Exp Allergy; 2014; 44(5):747-55. PubMed ID: 24447144
[TBL] [Abstract][Full Text] [Related]
17. Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity.
Moore A; Burrows AK; Rosenkrantz WS; Ghubash RM; Hosgood G
Vet Dermatol; 2023 Dec; 34(6):532-542. PubMed ID: 37395162
[TBL] [Abstract][Full Text] [Related]
18. Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol.
Rosman Y; Confino-Cohen R; Goldberg A
Int Arch Allergy Immunol; 2017; 174(1):45-51. PubMed ID: 28950273
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
20. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
